Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

Mayuko Kanayama; Jun Luo

doi:10.1016/j.eururo.2020.04.053

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

Mayuko Kanayama, Jun Luo

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	181-183
Number of pages	3
Journal	European Urology
Volume	78
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2020.04.053
State	Published - Aug 2020

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2020.04.053

Cite this

@article{b3f2622744e5448ba2991238c38009ca,

title = "Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?",

author = "Mayuko Kanayama and Jun Luo",

note = "Funding Information: Conflicts of interest: Jun Luo has served on advisory boards for Sun Pharmaceutical Industries, Tolero Pharmaceuticals, and Janssen Oncology; has received institutional research funding from Sanofi, Orion Pharma, Mirati Therapeutics, Gilead Sciences, Astellas Pharma, Calibr, Trovagene, Pandomedx, and Constellation Pharmaceuticals; and is an institutional co-inventor of a technology assigned to Johns Hopkins University and licensed to Tokai Pharmaceuticals, a technology licensed to Qiagen, and a technology licensed to A&G Pharmaceuticals. Mayuko Kanayama has nothing to disclose.",

year = "2020",

month = aug,

doi = "10.1016/j.eururo.2020.04.053",

language = "English (US)",

volume = "78",

pages = "181--183",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Predictive Biomarkers in Prostate Cancer

T2 - Is It Time To Go “All In” on Liquid Biopsies?

AU - Kanayama, Mayuko

AU - Luo, Jun

N1 - Funding Information: Conflicts of interest: Jun Luo has served on advisory boards for Sun Pharmaceutical Industries, Tolero Pharmaceuticals, and Janssen Oncology; has received institutional research funding from Sanofi, Orion Pharma, Mirati Therapeutics, Gilead Sciences, Astellas Pharma, Calibr, Trovagene, Pandomedx, and Constellation Pharmaceuticals; and is an institutional co-inventor of a technology assigned to Johns Hopkins University and licensed to Tokai Pharmaceuticals, a technology licensed to Qiagen, and a technology licensed to A&G Pharmaceuticals. Mayuko Kanayama has nothing to disclose.

PY - 2020/8

Y1 - 2020/8

UR - http://www.scopus.com/inward/record.url?scp=85084233702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084233702&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.04.053

DO - 10.1016/j.eururo.2020.04.053

M3 - Editorial

C2 - 32376139

AN - SCOPUS:85084233702

SN - 0302-2838

VL - 78

SP - 181

EP - 183

JO - European Urology

JF - European Urology

IS - 2

ER -

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this